PHASE 2A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECT OF THE HYPOXIA-INDUCIBLE FACTOR (HIF) PROLYL-4-HYDROXYLASE (PHD) INHIBITOR, DAPRODUSTAT ON EXERCISE PERFORMANCE IN PATIENTS WITH CHRONIC LUNG DISEASE AND ANAEMIA

Registry ID

208629

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

GLAXOSMITHKLINE INC

Last update

2018-11-01

Conditions

• ANEMIA
• LUNG DISEASE

Related clinical trials

• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ALN-CFB, AN INVESTIGATIONAL SIRNA THERAPEUTIC AGAINST COMPLEMENT FACTOR B, IN PARTICIPANTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND PERSISTENT ANEMIA ON APPROVED C5-INHIBITOR THERAPY
• A PHASE 2, RANDOMIZED, OPEN-LABEL, STUDY OF MOMELOTINIB IN PARTICIPANTS WITH ANEMIA DUE TO LOW-RISK MYELODYSPLASTIC SYNDROME
• AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH FIBROTIC LUNG DISEASE
• REDUCING RESPIRATORY SYMPTOMS OF PULMONARY IRRADIATION IN INTERSTITIAL LUNG DISEASE (RESPIRE-ILD): A 2X2 FACTORIAL RANDOMIZED PHASE II TRIAL TESTING N-ACETYL CYSTEINE AND DEXAMETHASONE
• A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VS EPOETIN ALFA FOR THE TREATMENT OF ANEMIA DUE TO REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS-R) VERY LOW, LOW, OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS) IN ERYTHROPOIESISSTIMULATING AGENT (ESA)-NAIVE PARTICIPANTS WHO ARE NON-TRANSFUSION DEPENDENT (NTD): THE ¿ELEMENT-MDS¿ TRIAL
• FEASIBILITY AND EFFICACY OF INTRAVENOUS FERRIC DERISOMALTOSE TO CORRECT PRE-OPERATIVE IRON-DEFICIENCY ANEMIA IN PATIENTS UNDERGOING GYNECOLOGIC ONCOLOGY SURGERY: A PILOT RANDOMIZED DOUBLE BLINDED PARALLEL GROUP PLACEBO-CONTROLLED STUDY

View on source registry